bevacizumab
Start here
The phase 3 PRABITAS trial showed that a 14-day schedule of trifluridine-tipiracil plus bevacizumab was non-inferior to the 28-day schedule for overall survival. Conducted in refractory metastatic colorectal cancer, the 14-day schedule had lower haematological and gastrointestinal toxicity; the results support the simplified schedule as the new standard for this combination.
Excerpted from thelancet.com
Coverage timeline
Follow the coverage to see the different angles.
- thelancet.com[Articles] 14-day versus 28-day trifluridine–tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan
The phase 3 PRABITAS trial showed that a 14-day schedule of trifluridine-tipiracil plus bevacizumab was non-inferior to the 28-day schedule for overall survival. Conducted in refractory metastatic colorectal cancer, the 14-day schedule had lower haematological and gastrointestinal toxicity; the results support the simplified schedule as the new standard for this combination.
- doi.orgPractical Review of Role and Usage of Corticosteroids in Modern Neuro-Oncology Care
Corticosteroids are an important treatment for neuro-oncology patients and should be used only as a temporary measure to relieve tumor mass effect, dosed once or twice daily with the second dose no later than early afternoon. Long-term use can affect multiple systems including endocrine, immune, and gastrointestinal, increase complications, and may weaken the efficacy of immunotherapy and chemoradiation; steroid-sparing regimens such as bevacizumab have been used to reduce toxicity. The review recommends the lowest effective dose with tapering as soon as possible, with special consideration of steroid effects during immunotherapy and imaging response assessment.
- Neurol Clin PractPractical Review of Role and Usage of Corticosteroids in Modern Neuro-Oncology Care
This practical review recommends corticosteroids only as a temporary measure for mass effect in neuro-oncology patients, at the lowest effective dose once or twice daily (the second dose no later than early afternoon), tapered off as soon as possible. Long-term use increases adverse effects across endocrine, immune, dermatologic, gastrointestinal, orthopedic, and neuropsychiatric systems, and weakens the efficacy of immunotherapy and chemoradiation. Steroid-sparing options such as bevacizumab have been used to reduce toxicity, and steroid effects on tumor response are now formally incorporated into imaging response assessment.
Heat trend for this story
Heat now 47·Peak in the comparable set 67 (Oct 25 00:00)·Change over 24h in the comparable set +5800%·Participants now 8
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.